Withanolide Encyclopedia — Scientific Background

What Are Withanolides?

Withanolides are a family of naturally occurring C₂₈ steroidal lactones unique to Ashwagandha (Withania somnifera), and are considered the major active components responsible for the adaptogenic, neuroprotective, and anti-inflammatory properties of this medicinal herb. Withanolide A (CAS 32911-62-9) is the most extensively studied withanolide, with the molecular formula C₂₈H₃₈O₆ and a molecular weight of 470.6 g/mol. Withanolide D (CAS 30655-48-2) has the same molecular formula and molecular weight.

Botanical Source

Withanolides are extracted from the roots, leaves, and berries of Withania somnifera (L.) Dunal, a member of the Solanaceae family commonly known as Ashwagandha or Indian ginseng. The plant is native to India, the Middle East, and parts of Africa, and has been used in Ayurvedic medicine for over 3,000 years. Withanolides are biosynthesized through the mevalonate pathway and are structurally characterized by a steroid nucleus with a δ-lactone ring. The content and profile of withanolides vary significantly depending on the plant part, cultivation conditions, and extraction method.

Mechanisms of Action

Neuroprotective Mechanisms — Multi-Target Actions

Withanolides enhance memory and provide significant neuroprotection both in vitro and in vivo. They inhibit amyloid-β protein oligomer aggregation, prevent tau protein hyperphosphorylation, and exert antioxidant effects by modulating the Keap-1/Nrf2 pathway. In addition, they inhibit acetylcholinesterase and pseudo-cholinesterase, thereby improving memory and cognition. Withanolides also reduce inflammation by lowering pro-inflammatory markers, such as IL-1β, IL-6, MCP-1, and TNF-α, and prevent neuronal apoptosis by decreasing Bax/caspase-3 and cyto-c expression. They enhance neuroplasticity by increasing the levels of brain-derived neurotropic factor (BDNF) and glial fibrillary protein (GFAP).

Anti-Inflammatory Activity — NF-κB Pathway Modulation

Withanolides, a family of steroid-derived molecules unique to Ashwagandha, have been shown to modulate inflammatory pathways in animal models. Their anti-inflammatory effects are mediated through suppression of NF-κB signaling and reduction of pro-inflammatory cytokine production. This mechanism contributes to their therapeutic potential for inflammatory conditions and neurodegenerative disorders.

Adaptogenic and Stress-Modulating Effects

Withanolides modulate the hypothalamic-pituitary-adrenal (HPA) axis, supporting healthy cortisol levels and stress responses. Clinical trials have confirmed cognitive enhancement, memory improvement, and stress relief in patients with Alzheimer‘s disease. A clinical trial is evaluating Ashwagandha root extract (standardized to <0.9% withanolides) at 1,000 mg daily for 3 months in adults with long COVID, assessing functional status and symptom burden.

Thyroid Function Modulation

In a placebo-controlled trial in which individuals with subclinical hypothyroidism were treated with standardized aqueous Ashwagandha root extract containing 5% withanolides, the results showed that serum thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) levels were significantly decreased. This suggests that withanolides may modulate thyroid hormone metabolism.

The Bioavailability Challenge

Despite their broad therapeutic potential, native withanolides present significant bioavailability challenges. Withanolides have poor bioavailability, water solubility, and permeability. Their low bioavailability due to environmental and gastrointestinal factors limits efficacy. These limitations have driven the development of advanced delivery systems, including liposomes, niosomes, polymeric nanoparticles, and gold nanoparticles.

liposomal Withanolide

Liposomal encapsulation of withanolides provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the withanolide molecules, forming a nanoscale vesicle that enhances solubility, stability, and cellular uptake. This delivery system:

• Increases overall solubility by 14-fold and aqueous solubility by 1.3-fold

• Enhances stability and bioavailability by more than 95%

• Achieves 125 nm particle size with 83.65% encapsulation efficiency

• Demonstrates sustained release of 58.5 ± 2.93% over 6 hours in simulated intestinal fluid

• Enhances cellular uptake and therapeutic efficacy in vitro

PEGylated nano-liposomal Withanolide A was synthesized using the thin film hydration method with high stability, having a particle size of 125 nm and 83.65% encapsulation efficiency. In vitro studies revealed that encapsulated Withanolide A showed increased sustained release and significantly reduced cell growth in DLA and EAC cell lines compared to free Withanolide A.

Clinical Evidence

Alzheimer‘s Disease — Clinical Trials

Clinical trials have confirmed cognitive enhancement, memory improvement, and stress relief in patients with Alzheimer’s disease. Current in vitro and in vivo data indicate that withanolides have strong potential to be effective treatments for Alzheimer‘s disease through antioxidant and anti-inflammatory activities, inhibition of amyloid-β aggregation, tau hyperphosphorylation, and acetylcholine enhancement.

Long COVID — Ongoing Clinical Trial

The APRIL Trial is a randomized, double-blind, placebo-controlled trial evaluating Ashwagandha root extract tablets (standardized to <0.9% withanolides) at 1,000 mg daily for 3 months in adults living with long COVID. The trial will assess functional status and symptom burden using the Post-COVID Functional Status Scale as the primary outcome.

Subclinical Hypothyroidism

In a placebo-controlled trial in which individuals with subclinical hypothyroidism were treated with standardized aqueous Ashwagandha root extract containing 5% withanolides, serum TSH, T3, and T4 levels were significantly decreased, demonstrating the thyroid-modulating effects of withanolides.

Tension-Type Headache

A comparative clinical trial evaluated standardized Ashwagandha as a neuro agent in tension-type headache, with a mean frequency of headaches in the treatment group reduced by 42% (p < 0.005).

Cancer — Phase 1 Trial

Withanolide A is engaged in clinical trials to determine its impact on various cancer types. Phase-1 trial studies on osteosarcoma patients were performed using a 3 + 3 design with four doses (72, 108, ...). Preclinical studies have demonstrated that liposomal-mediated Withanolide A drug delivery systems were highly effective against pancreatic cancer compared to free Withanolide A.

Arthritis — Preclinical Evidence

When Withanolide A was encapsulated in mannose liposomes, it was found to treat arthritis in rats compared to free Withanolide A, demonstrating the enhanced therapeutic efficacy of liposomal delivery for inflammatory conditions.

Safety and Regulatory

Ashwagandha is generally well tolerated at commonly used doses. Most studies use 250 mg to 600 mg of Ashwagandha root extract per day, often standardized to withanolides and split into one or two doses, with 300 mg twice daily being a common regimen for stress and sleep support. Higher intakes of 1,000 mg or more per day have been used short term, but they raise the risk of stomach upset, drowsiness, and rare liver injury, and most trials only ran 8 to 12 weeks.

Regulatory status varies by region:

• United States — Ashwagandha extract standardized to withanolides is regulated as a dietary supplement ingredient. It is available in the United States as a dietary supplement and is widely commercialized in stress-management and adaptogen products.

• European Union — Ashwagandha is authorized for use in food supplements in EU member states. The European Medicines Agency (EMA) has published a monograph on Withania somnifera root for traditional use in the relief of stress and mild anxiety.

• India — Ashwagandha is a well-established Ayurvedic medicine with a long history of traditional use. The Ministry of AYUSH regulates its use as a medicinal herb.

• Global Standards — Withanolide A is available as a USP Reference Standard (Catalog No. 1719500). Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

Precautions: Rare cases of liver injury have been reported with Ashwagandha supplementation, and individuals with pre-existing liver conditions should consult a healthcare professional before use. Ashwagandha may affect thyroid hormone levels and should be used with caution in individuals with thyroid disorders. Pregnant or lactating women and children should consult a healthcare professional before use. Ashwagandha may interact with immunosuppressant medications, sedatives, and thyroid medications.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

99$/KG